Loading…
the sparker alert will let you know when a significant move starts with an audio alert, so You'll never miss an Opportunity.
Gridai Technologies Corp, Formerly Known As Entero Therapeutics Inc, Is A Late Clinical-Stage Biopharmaceutical Company Focused On The Development Of Targeted, Non-Systemic Therapies For Gastrointestinal (Gi) Diseases. The Company'S Programs Address Unmet Needs In Gi Health And Include: Latiglutenase, A Phase 3-Ready, Potentially First-In-Class, Targeted, Oral Biotherapeutic For Celiac Disease; Capeserod, A Selective 5-Ht4 Receptor Partial Agonist For Indications Including Gastroparesis; And Adrulipase, A Recombinant Lipase Enzyme Designed To Enable The Digestion Of Fats And Other Nutrients In Cystic Fibrosis And Chronic Pancreatitis Patients With Exocrine Pancreatic Insufficiency.